Tax-related share sale by Privia (PRVA) legal chief after RSU vesting

Rhea-AI Filing Summary

Privia Health Group EVP & General Counsel Edward C. Fargis reported two stock sales that were required to cover taxes on vested restricted stock units. On March 6, 2026, he sold 4,394 shares at $23.15 per share, followed by 4,949 shares at $22.84 per share on March 9, 2026. The footnote explains these were nondiscretionary “sell to cover” transactions to satisfy tax withholding obligations, rather than elective open-market sales. After the transactions, he directly owned 83,711 shares of Privia Health Group common stock.

Insights

Equity compensation and insider-transactions analyst

These were routine tax-related sales tied to RSU vesting, not discretionary selling.

The filing shows Edward C. Fargis, EVP & General Counsel of Privia Health Group, selling a total of 9,343 common shares at prices between $22.84 and $23.15. The footnote clarifies the sales were nondiscretionary “sell to cover” transactions for tax withholding on restricted stock unit vesting.

Because the transactions were driven by tax obligations rather than active portfolio decisions, they carry limited signaling value about his view of the stock. Following the sales, he still directly holds 83,711 shares, indicating he maintains a substantial equity position. Overall, this appears to be routine equity-compensation administration with neutral impact.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Fargis Edward C

(Last) (First) (Middle)

PRIVIA HEALTH GROUP, INC.

950 N. GLEBE. RD., SUITE 700

(Street)

ARLINGTON VA 22203

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Privia Health Group, Inc. [ PRVA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP & General Counsel

3. Date of Earliest Transaction (Month/Day/Year)
03/06/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, $0.01 par value per share	03/06/2026		S(1)		4,394	D	$23.15	88,660	D
Common Stock, $0.01 par value per share	03/09/2026		S(1)		4,949	D	$22.84	83,711	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sales reported in this Form 4 represent nondiscretionary sales of shares required to be sold by the Reporting Person pursuant to sell to cover transactions to satisfy tax withholding obligations in connection with the vesting and settlement of restricted stock units.

Remarks:

	/s/ Anita Beth Adams, as attorney-in-fact	03/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Privia Health Group (PRVA) report for Edward C. Fargis?

Privia Health Group reported that EVP & General Counsel Edward C. Fargis sold 9,343 common shares in two transactions. He sold 4,394 shares at $23.15 and 4,949 shares at $22.84, both tied to equity compensation tax obligations rather than discretionary trading.

Why did Edward C. Fargis sell Privia Health Group (PRVA) shares in this Form 4?

According to the Form 4 footnote, the reported sales were nondiscretionary “sell to cover” transactions. The shares were sold solely to satisfy tax withholding obligations arising from the vesting and settlement of restricted stock units, not as elective open-market sales for portfolio reasons.

How many Privia Health Group (PRVA) shares did Edward C. Fargis sell and at what prices?

Edward C. Fargis sold a total of 9,343 Privia Health Group common shares. He sold 4,394 shares at $23.15 per share on March 6, 2026, and 4,949 shares at $22.84 per share on March 9, 2026, all in tax-related transactions.

How many Privia Health Group (PRVA) shares does Edward C. Fargis hold after these transactions?

After completing the tax-related sales, Edward C. Fargis directly holds 83,711 shares of Privia Health Group common stock. This remaining position, reported in the Form 4, indicates he continues to maintain meaningful equity exposure following the restricted stock unit vesting events.

Were the Privia Health Group (PRVA) share sales by Edward C. Fargis open-market trades?

The transactions are coded as sales but described as nondiscretionary “sell to cover” events. While executed as market sales, the Form 4 footnote explains they were required to cover tax withholding on restricted stock unit vesting, rather than voluntary timing decisions by the executive.

Does this Privia Health Group (PRVA) Form 4 suggest a change in insider sentiment?

The Form 4 primarily reflects routine equity-compensation mechanics, not a strategic shift. Shares were sold to pay taxes upon RSU vesting, which is common for executives. With 83,711 shares still held directly, the filing suggests administrative activity more than a change in sentiment.